Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24101584 | 0.87 | LRRK2 (0.34) | MCHR1HPGDHTTHSD17B10MEN1 | |
| SCHEMBL30339427 | 0.87 | LRRK2 (0.34) | MCHR1HPGDHTTHSD17B10MEN1 | |
| SCHEMBL30339762 | 0.83 | HPGD (0.40) | MCHR1HRH3HPGDHTTHSD17B10 | |
| SCHEMBL24101590 | 0.83 | HPGD (0.40) | MCHR1HRH3HPGDHTTHSD17B10 | |
| SCHEMBL25846155 | 0.79 | PTGS2 (0.42) | MCHR1HRH3HPGDHTTHSD17B10 | |
| SCHEMBL25846134 | 0.78 | MCHR1 (0.49) | MCHR1HRH3HRH1CNR1HTR6 | |
| SCHEMBL24101588 | 0.74 | MCHR1 (0.46) | MCHR1HPGDHTTHSD17B10MEN1 | |
| SCHEMBL30339469 | 0.74 | MCHR1 (0.46) | MCHR1HPGDHTTHSD17B10MEN1 | |
| SCHEMBL25846111 | 0.72 | MCHR1 (0.52) | MCHR1HRH3CNR1HTR6KCNH2 | |
| SCHEMBL24102117 | 0.71 | NR3C1 (0.40) | MEN1KMT2ABAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | GAP43, GRIN2A, GRIN2C | MCHR1 320/4885HRH3 1112/4885HPGD 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.